1. David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California;
2. Royal Brompton and Harefield Hospitals, London, United Kingdom;
3. Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom; and
4. Yale School of Medicine, Yale University, New Haven, Connecticut;
5. Pulmonary and Critical Care Medicine, Allergy & Immunology, Brigham and Women’s Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts;
6. IKF Pneumologie Mainz, Mainz, Germany;
7. Thoraxklinik Heidelberg, Heidelberg, Germany;
8. Respiratory and Immunology, BioPharmaceuticals Medical,
9. Biometrics, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden;
10. Late-Stage Development, and
11. Global Development,
12. Global Medical Affairs, and
13. University of Leicester, Leicester, United Kingdom
14. Biometrics,
15. Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland;
16. Translational Medicine, Amgen, Thousand Oaks, California;